Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001231919-25-000494
Filing Date
2025-11-14
Accepted
2025-11-14 16:28:55
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 24696
2 JOINT FILING AGREEMENT ex-99-11142025_091158.htm EX-99.1 8540
  Complete submission text file 0001231919-25-000494.txt   35112
Mailing Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453 (781) 312-3013
Jade Biosciences, Inc. (Subject) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92668 | Film No.: 251486972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A